Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine if plerixafor can make CLL/SLL (Chronic
Lymphocytic Leukemia/ Small Lymphocytic Lymphoma) cells more sensitive to being killed by
rituximab, an anti-cancer drug that is commonly used in treating CLL and SLL. In this study,
plerixafor will be added to standard treatment with rituximab. Subjects will be monitored to
see how well they tolerate the use of these drugs together and how well they work to treat
the leukemia.
The primary objective is to determine the maximum tolerated dose (MTD) of plerixafor when
combined with rituximab as treatment for previously treated patients with CLL or SLL.